Gambaran Usia dan Stadium Klinis Pasien Kanker Payudara yang dilakukan Pemeriksaan Imunohistokimia di Rumah Sakit Abdul Wahab Sjahranie pada Tahun 2018
Abstract
ABSTRACK
Breast cancer still occupies the highest incidence of all types of malignancies in women. Based on data recorded at Abdul Wahab Sjahrenie Hospital, 200 new cases are found each year. Immunohistochemical profile examination has been used extensively as a basis for classifying breast cancer molecularly. Expression of hormone receptors (ER, PR) and HER-2 found in immunohistochemical examinations are useful for determining therapeutic options that fit the patient's needs. The purpose of this descriptive study was to determine the characteristics of the immunohistochemical profile of breast cancer patients in Abdul Wahab Sjahranie Regional Hospital Samarinda in the January-December 2018 period based on age and clinical stage that had been examined by immunohistochemical examination including the expression of ER PR, Ki-67 and HER2. Method: This study used a cross-sectional descriptive study design by taking secondary data from breast cancer patients who had performed immunohistochemical examinations at Abdul Wahab Sjahranie Regional Hospital Samarinda in the January 2018 - December 2018 period. From 479 breast cancer patients came to Abdul Wahab Regional Hospital Sjahranie Samarinda, only 177 (37.18%) patients did immunohistochemical examinations. Most patients aged 40-49 were 65 patients (36.7%) had breast cancer, the highest clinical stage IIIB with 92 cases (52%), the Ki-67 with severe highest interpretation, range> 30% with 73 patients (41.2%), more positive ER than negative, in 93 patients (52.5%), while negative examination results 84 patients (47.5%). PR is the same as ER, which is 96 patients (54.2%), while negative examination results are 81 patients (45.8%). Most HER-2 results were negative, in 109 patients (61.6%). In this study the highest number of cases of breast cancer patients ranged between the ages of 40-49 years and at least aged 70 years and above. The clinical stage is most often found in stage IIIB (advanced). Ki-67 examination was found most frequently in severe interpretations. Examination of estrogen receptors is found to be most widely in positive interpretation. Positive progesterone tests to be most widely than negative examinations. Her-2 examination was found to be most widely in negative interpretation
Keywords: Immunohistochemical examination, Hormone receptors, HER-2, Clinical Stadium
References
Anggorowati, L. (2013). "Faktor Risiko Kanker Payudara Wanita" KEMAS: Jurnal
Kesehatan Masyarakat, 8(2), 121-126
ASCO. (2016). Breast cancer :overview. Dipetik maret 2019, dari cancer. Net; American
sosiety of clinical oncology (ASCO); http://www.cancer.net/cancer-types/breastcancer/overview
Asie, A., & Sampepajung, D. (2011). Correlation between HER-2 Expression with the Age
and Histologycal Grading on Female Breast Cancer in Wahidin Sudirohusodo
General Hospital. Makassar. Surgical Oncology Sub Division, Faculty of Medicine
Hasanuddin University
Badowska-Kozakiewicz, A. M., Sobol, M. Patera, J., & Kozlowski, W. (2011).
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and
estrogen and progesterone receptors in invasive breast cancer in women. Warsaw:
Poland.
Benson, R.C.(2008). Buku Saku Obstetri danginekologi . jakarta :EGC
Brunicardi FC, Anderson DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB et al. 2010.
Schwartz’s Principles of Surgery. 9th edition. The united states of America: The
McGraw- Hill Companies, Inc.
Chen, X. S., Ma, C. D., Wu, J. Y., Lu, H. F., Wu, J., & et al. (2010). Molecular subtype
Approximated by Quantitative Estrogen Reseptor, Progesteron Reseptor and HER-2
can Predict The Prognosis Of Breast Cancer. Pubmed, 96(1):3-10.
Ciptadi I, GAN, et al. “Hubungan Subtipe Imunohistokimia Dengan Usia Pada Pasien
Kanker Payudara Di Rsup Sanglah Kota Denpasar” Vol. 6 No.3, Maret, 2017, EJurnal Medika
Desai, S. B., Moonim, M. T., Gill, A. K., Punia, R. S., Naresh, K. N., & Chinoy, R. F. (2009).
Hormone receptor status of breast cancer in India: a study of 798 tumours. Pubmed.
Dunnwald, L. K., Rossing, M. A., & Li, C. I. (2007, January 19). Hormone receptor status,
tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
United States of America.
Dankert, C., sinn, B. V., Muller, B. M., Untch, M., von, M. G., dan loibl, S. (2011).
Prediction of response to neoadjuvant chemotherapy: New biomarker Approaches
and Concepts. Breast care. 6:265-272.
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., Senn, H. J., &
Panel members. (2005). Meeting Highlights: International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2005. Annals of Oncology. Oxford
Academic.
Gray M.J., Gallick G.E (2010). The Role Of Oncogene Activation In Tumor Progression.
Mechanisms Of Oncogenesis. USA: Springer
Hasan, I., Tarcisia, T., Agnestina, Cornain, S., dan Nasar, I. M. (2013). Ki-67 marker usefull
for classification of malignant invasive ductal breast cancer. Universa medicina , 32:
-186.
IARC.(2018) GLOBOCAN 2018. Dipetik 24 Januari 2019, dari GLOBOCAN 2018:
Estimated Camcer Incidence, Mortality And Pravelence Worldwide In 2018:
http://globocan.iarc.fr/pages/fact_sheet_cancer.aspx
Jatiluhur, I. M., Yantisetiasti, A., Hassan, A. H., Hernowo, B.S. (2014). Hubungan antara
HER-2/neu dan ki-67 dengan respon kemoterapi neoadjuvan pada karsinoma
payudara lanjut lokal. Majalah patologi. JOM FK, 3(1):1-3.
Jeong S., et al. (2011). Hormone Receptor Status Rather Than HER2 Status is Significantly
Associated with Increased Ki-67 and pS53 Expression in Triple- negative Breast
Carcinomas, and High Expression of Ki-67 but Not p53 is Significantly Associated
with Axillary Nodal Metastasis in Triple-negative and High-Grade NonTripleNegative Breast Carcinomas. Am J ClinPathol 135: 230-23
Jerjees, D.A., Alabdullah M., Green, A.R, et al. (2014). Prognostic and biological
significance and her 2 expression in the luminal class of breast cancer. Breast
cancer res treat, 145: 317-330
KEMENKES RI. (2015) Panduan Penatalaksanaan Kanker Payudara. Jakarta:
KEMENKES RI.
KPKN. (2014). Pedoman Nasional Pelayanan Kanker Payudara. Jakarta: Kementrian
Kesehatan RI.
Komite Penanggulangan Kanker Nasional. (2014). Pedoman Nasional Pelayanan
Kanker Payudara. Jakarta: Kementrian Kesehatan RI.
Lal, P., Tan, L. K., & Chen, B. (2005, April). Korelasi Status HER-2 Dengan Reseptor
Estrogen dan Progesteron dan Fitur Histologis pada Karsinoma Payudara Invasif.
American Journal of Clinical Phatology.
Lester,S.C. (2010). The Breast. In: Kumar, F., Abbas,A.K., Fausto, N, N., Aster,J.C., editors.
Robbins and cotran pathologic Basic Of Disease Eighth Edition. Philadelphia:
Saunders Elsevier.
Liao, G.S.,Chou, Y. C., & Hsu, H. M. (2015). The Prognostik Value Of Lymph Node Status
Among Breast Cancer. Zhonghua Yi Xue Zha Zhi, 1-7.
Lincoln, J. dan Wilensky. (2008). Kanker Payudara diagnosis dan solusinya. Jakarta:prestasi
pustakaraya.
Nani, D. 2009. Hubungan Umur Awal Menopause dan Status Penggunaan Kontrasepsi
Hormonal dengan Kejadian Kanker Payudara Jurnal Keperawatan Soedirman, 4 (3):
-106.
Nelson, R. (2008). AACR FCPR : ER/PR-Negative Brcast Cancer Linkod to Race and
Socioeconomic Status. medscape.
NCCN.(2018). Breast Cancer Screaning And Diagnosis. Dipetik januari 2019, dari NCCN
Clinical Practice Guidelines In Oncology (NCCN Guideline):
http://www.nccn.org/profesionals/physician_gls/pdf/breast-screening.pdf
PPKP. (2016). Panduan Penatalaksanaan Kanker Payudara, Komite Penanggulangan
Kanker Nasional. Kementerian Kesehatan Republik Indonesia: Jakarta
Santer, Suyatno, Kamal Basri Siregar. (2013). Profil ekspresi HER2 dan Ki67 pada berbagai
kelompok usia penderita kanker payudara di RSUP H. Adam Malik Medan. Medan:
Majalah Kedokteran Nusantara • Volume 46 • No. 3
Saika, K. dan Sobu T. (2009). Epidemiology of breast cancer in japan and US. JMAJ. 52 (1):
-44.
Shanaz, N. (2010). Profil Hormonal Reseptor Pada Pemeriksaan Imunohistokimia pada
pasien kanker payudara Di RSUD Dr Soetomo Pada Tahun 2009 [Skripsi]. Surabaya,
Jawa Timur. Indonesia
Siegel, R.,. Miller.K.D, Ahmedin.J, (2018). Global Cancer Statistic 2017: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries.
France : International Agency for Reasearch on Cancer.
Stopeck Payudara, A. T., Downey, L., Lang, J., Thompson, P. A., Harris, J., Gohel, M. S., et
al. (2012). Kanker. Diakses dari: http://emedicine.mcdscape.com/article/ 1947145-
overview.
Sulistyowati. (2012). Stadium Kanker Payudara Ditinjau dari Usia dan Paritas Ibu di Unit
Rawat Jalan RSUD Dr. Soegiri Kabupaten Lamongan. Jurnal Surya, 3(13): 9-15
Suyatno, & Pasaribu, E. (2014). Bedah Onkologi Diagnosis dan Terapi (Vol. 2). (S. (.
dr. Suyatno, Ed.) Jakarta: CV Sagung Seto.
Susilo, I. 2012. Ekspresi Protein Er (Estrogen Receptor) Pada Kanker Payudara Derajat
Keganasan Baik, Sedang Dan Buruk. Jurnal Ners. 7(1): 88–93
Rahman, A., Sampepajung, D., & Hamdani, W. (2015, Juny 11). Hubungan Ekspresi HER-2
/ neu dan Hormon Reseptor dengan Grading Histopatologi pada Penderita Kanker
Payudara Wanita Usia Muda Dipetik 5desember 2019, dari E_Jurnal Program
Pascasarjana Universitas
Hasanuddin:http://pasca.unhas.ac.id/jurnal/files/1f36895c326749dc29ec540a8clabfn .
Rismala. (2010) Menopause dan Keluhannya. Jakarta: Rineka Cipta.
Wiguna, N. I., & Manuaba, T. W. (2012). Karakteristik Pemeriksaan Imunohistokimia pada
Pasien Kanker Payudara di RSUP Sanglah Periode 2003-2012.E-Jurnal Medika
Udayana 3(7)1-13
Xing Tan Q, Q Qin Hong, Ping Yang W, Guo Mo Q. dan Yuan Wei C. Nilai Prognostik
Ekspresi Ki67 pada Kanker Payudara HR-negatif Sebelum dan Setelah Kemoterapi
Neoadjuvant. Int J Clin Exp Pathol. 7 (10): 6862-6870
Yerushalmi, R., Woods R., Ravdin, P.M., Hayes, M. M., gelmon, K. A. (2010). Ki-67 in
breast cancer : prognostic and predictive potential. Lancet Oncol. 11: 174-183.
1016/S147-2045(09)70262-1
Yulianti, Iin, et al. "Faktor-faktor Risiko Kanker Payudara (Studi Kasus Pada Rumah Sakit
Ken Saras Semarang)" Jurnal Kesehatan Masyarakat Universitas Diponegoro, vol.
, no. 4, 2016, pp. 401-409, Neliti
Copyright (c) 2020 Ade Yusuf Yulianto, Hadi Irawiraman, P.M.T. Mangalindung Ompusunggu
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Proposed Policy for Journals That Offer Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
= 1562 times
PDF downloaded = 799 times
